HHS Office of Inspector General Drops Challenge To Forest CEO Solomon
This article was originally published in The Pink Sheet Daily
Executive Summary
Amid drama from dissident investor Carl Icahn, Forest is relieved of the fear that the federal OIG could bar its CEO from contracting with government health care programs.
You may also be interested in...
Solomon To Step Aside As Forest Exec; Icahn Wins Another Victory
President and CEO of Forest Laboratories Howard Solomon will retire at the end of the year. Activist investor Carl Icahn has long inveighed against the 85 year-old exec. This could signal a renewed effort to get Forest back on track, now that its Lexapro losses have slashed revenue and a Namenda expiry looms.
Forest Holds Off Icahn, But Battle Likely Looms
Forest shareholders elect the company's slate of board members at its annual meeting, shooting down activist investor Carl Icahn's picks.
Forest Holds Off Icahn, But Battle Likely Looms
Forest shareholders elect the company's slate of board members at its annual meeting, shooting down activist investor Carl Icahn's picks.